Literature DB >> 8357118

Chronic active hepatitis: the challenge for a new nomenclature.

A J Czaja1.   

Abstract

OBJECTIVES: To review the etiologic agents and pathogenic mechanisms of chronic active hepatitis, to describe the current nomenclature for this disease and highlight its shortcomings, and to propose guidelines for change. DATA SOURCES: Relevant references were identified through a MEDLINE search (1982 to 1992), through prominent review articles and texts, and through a personal library of journals and reprints. Additional references were selected from the bibliographies of identified articles. STUDY SELECTION: All pertinent articles on the etiologic agents, pathogenic mechanisms, and nomenclature of chronic active hepatitis were studied. DATA SYNTHESIS: Subtypes of chronic active hepatitis can be defined by etiologic agent or immunoserologic marker, and these subtypes may have different clinical features, prognoses, pathogenic mechanisms, and treatments. An unauthorized jargon has evolved to accommodate these subtypes, and it may wrongly or prematurely connote their validity. Patients with cryptogenic disease, mixed viral and immunologic features, and atypical findings lack a formal designation. No established mechanism exists for modification of the nomenclature.
CONCLUSIONS: Chronic hepatitis can be subclassified into different subtypes that are defined by etiologic agent or by predominate pathogenic mechanism. A new nomenclature must be based on this knowledge. Formal mechanisms must be established to revise the nomenclature and to promulgate change.

Entities:  

Mesh:

Year:  1993        PMID: 8357118     DOI: 10.7326/0003-4819-119-6-199309150-00011

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  12 in total

Review 1.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

Review 2.  Variant forms of autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

3.  Anti-envelope antibodies in anti-hepatitis C virus (HCV) positive patients with and without liver disease.

Authors:  M Pirisi; P Ferroni; C Fabris; P Toniutto; G Soardo; D Vitulli; V Gasparini; E Bartoli
Journal:  Infection       Date:  1995 Jan-Feb       Impact factor: 3.553

Review 4.  Hepatitis C: diagnosis and treatment.

Authors:  I Scotiniotis; C A Brass; P F Malet
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

Review 5.  Autoimmune hepatitis. Evolving concepts and treatment strategies.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 6.  The overlap syndromes of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

Review 7.  Drug therapy in the management of type 1 autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

Review 8.  Chronic viral hepatitis B and C: an argument against the conventional classification of chronic hepatitis.

Authors:  M Schmid; R Flury; H Bühler; J Havelka; P J Grob; P U Heitz
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

9.  Validation of scoring system for diagnosis of autoimmune hepatitis.

Authors:  A Czaja; H A Carpenter
Journal:  Dig Dis Sci       Date:  1996-02       Impact factor: 3.199

10.  Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis.

Authors:  A J Czaja; K D Pfeifer; R H Decker; A S Vallari
Journal:  Dig Dis Sci       Date:  1996-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.